Awakn Life Sciences Inc.

Recent News

  • Awakn Launches Digital Unit and Signs Agreement with the University of Exeter to Improve Addiction Treatment Through Artificial Intelligence and Big Data

    London, United Kingdom--(Newsfile Corp. - April 12, 2021) - Awakn Life Sciences Inc., a clinical-biotech company researching, developing, and delivering psychedelic medicine to treat addiction and other mental health conditions, today launched 'Awakn Digital', a new unit focused on using advanced analytics to improve the effectiveness of Psychedelic-Assisted Psychotherapy in treating Addiction. Awakn deepened its partnership with the University of Exeter to apply the latest developments in digital, technology and innovation in healthcare to tackle addiction.Awakn previously announced an...

    2021-04-12 9:54 AM ET
  • Awakn Acquires Proprietary Next Generation MDMA and Ketamine Data from Prof. David Nutt

    London, United Kingdom--(Newsfile Corp. - March 9, 2021) -  Awakn Life Sciences Inc., a clinical-biotech company researching, developing, and delivering psychedelic medicine to treat addiction and other mental health conditions, today announced the acquisition of significant proprietary research data on next generation candidate MDMA and Ketamine molecules from Prof. David Nutt's Equasy Enterprises. In addition to the acquisition of the data, Prof. Nutt has been appointed as Head of Research to lead Awakn's next generation psychedelic molecule development programme.This latest...

    2021-03-09 8:00 AM ET
  • Awakn Announces Exclusive License Deal with the University of Exeter to Commercialise the 'Ketamine in the Reduction of Alcoholic Relapse' (KARE) Intervention Validated in a Phase II Clinical Trial

    London, United Kingdom--(Newsfile Corp. - March 2, 2021) - Awakn Life Sciences Inc., a clinical-biotech company researching, developing, and delivering psychedelic medicine to treat addiction and other mental health conditions, today announced an exclusive license to use and deliver the 'Ketamine in the Reduction of Alcoholic Relapse' (KARE) psychotherapy intervention, as validated in a Phase II clinical trial led by the University of Exeter.The KARE clinical research study, led by Prof. Celia Morgan of the University of Exeter, was a...

    2021-03-02 8:50 AM ET
  • Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World's First 'MDMA in Alcohol Use Disorder' Clinical Trial

    London, United Kingdom--(Newsfile Corp. - February 19, 2021) - Awakn Life Sciences Inc. announces today the publication of results from its CMO Dr. Ben Sessa's Bristol Imperial MDMA in Alcoholism (BIMA) trial, an open-label safety, tolerability and proof-of-concept study investigating the potential role for MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder (AUD).Results published today in the Journal of Psychopharmacology, show that MDMA-Assisted Psychotherapy (3,4-methylenedioxymethamphetamine) was well tolerated by all participants. No unexpected adverse events were observed, and psychosocial...

    2021-02-19 9:59 AM ET
  • Awakn Appoints James Collins, Ex-Accenture Strategy MD, as Chief Operating Officer

    London, United Kingdom--(Newsfile Corp. - January 25, 2021) - Awakn Life Sciences Inc., a biotechnology company focused on research, development, and delivery of psychedelic medicines for the treatment of mental health conditions, today announced the appointment of James Collins as Chief Operating Officer, effective January 2021.Collins joins from Accenture Strategy where he was a Managing Director (London) for several years, responsible for client relationship development, sales, delivery, and European & Global practise management. He is an industry thought leader with...

    2021-01-25 8:00 AM ET
  • Awakn Strengthens Scientific and Medical Leadership with Appointment of Chief Science Officer and Head of Ketamine Alcohol Use Disorder Practice

    Toronto, Ontario--(Newsfile Corp. - January 19, 2021) -  Awakn Life Sciences Inc., a biotechnology company focused on research, development and delivery of psychedelic medicines for the treatment of mental health conditions, today announced the appointment of Dr. Shaun McNulty, formerly at GlaxoSmithKline (GSK), as Chief Science Officer and Prof. Celia Morgan, from Exeter University, as Head of Ketamine-Assisted Psychotherapy for the company's Alcohol Use Disorder (AUD) Practice; both effective January 2021.Dr. McNulty joins as an experienced biotechnology executive with over...

    2021-01-19 8:00 AM ET
  • Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder

    Toronto, Ontario--(Newsfile Corp. - January 15, 2021) - Awakn Life Sciences announced today the selection of contract research organization ('CRO'), PRA Health Sciences (NASDAQ: PRAH), to conduct a Phase IIb trial studying the effectiveness of MDMA-Assisted Psychotherapy as a treatment for patients with Non-Physically Dependent ('Harmful Use') Alcohol Use Disorder ("AUD").Awakn's Phase IIb study will take place in the United Kingdom and will be a double-blind, placebo-controlled clinical trial designed to investigate the safety and efficacy of MDMA as a...

    2021-01-15 8:00 AM ET
  • Celia Morgan, Professor of Psychopharmacology at University of Exeter and Leading Ketamine Investigator, Joins AWAKN Life Sciences

    Toronto, Ontario--(Newsfile Corp. - October 2, 2020) - AWAKN Life Sciences Inc. ("AWAKN") is pleased to announce the appointment of Professor Celia Morgan to its Scientific Advisory Board (SAB).Celia Morgan is a Professor of Psychopharmacology at the University of Exeter in the United Kingdom. She is one Europe's leading Ketamine researchers & investigators and the academic lead for the Exeter Translational Addiction Partnership. Prof. Morgan's research focuses on examining both the benefits and side effects of recreational drugs on...

    2020-10-02 9:00 AM ET